Introduction

Allergy relief spans quick, over‑the‑counter (OTC) symptom control and physician‑directed, disease‑modifying immunotherapy you can take at home. This page explains when to use intranasal corticosteroids (INCS) and antihistamines, and when to step up to sublingual immunotherapy (SLIT)—including tablet label requirements (first‑dose supervision and epinephrine) and how custom liquid drops (off‑label in the U.S.) are prescribed and monitored by physicians. Last reviewed: November 9, 2025.

Non‑prescription options (symptom control)

OTC treatments reduce symptoms while you use them; they do not retrain the immune system.

• Intranasal corticosteroids (fluticasone, triamcinolone, budesonide)

• Best for congestion, sneezing, and runny/itchy nose when used daily.

• Onset: partial relief in 6–12 hours; maximal effect in several days.

• References: Wyndly clinical guides on nasal sprays and congestion management.

• Second‑generation oral antihistamines (cetirizine, fexofenadine, loratadine)

• Help itching, sneezing, and watery eyes; generally non‑sedating.

• References: Wyndly overview of antihistamines.

• Supportive measures

• Saline rinses, HEPA filtration, and exposure reduction (see Wyndly’s ways to treat allergy symptoms).

OTC therapies are appropriate for mild, intermittent symptoms or as add‑ons during immunotherapy. For persistent, life‑impacting, or multi‑season disease, disease‑modifying care is recommended.

Disease‑modifying care at home: Sublingual immunotherapy (SLIT)

SLIT exposes the immune system to tiny, regular doses of your allergens to build tolerance and reduce reactivity over time. Most patients notice improvement in 4–24 weeks; sustained benefit is “locked in” after ~3 years of therapy. Clinical reviews from major societies support SLIT’s safety and efficacy, with comparable long‑term outcomes to allergy shots in many indications.

Two forms used in the U.S.

1) FDA‑approved SLIT tablets (single‑allergen)

• Examples and key label rules (abbreviated):

• Timothy grass (GRASTEK), short ragweed (RAGWITEK), and house dust mite (ODACTRA).

• First dose must be administered under healthcare supervision with ≥30 minutes observation; prescribers must prescribe/train patients to carry auto‑injectable epinephrine for home dosing thereafter. Age ranges include: GRASTEK 5–65; RAGWITEK 5–65; ODACTRA 5–65 (FDA expanded to ages 5–11 on Feb 28, 2025). Sources: FDA‑approved prescribing information for GRASTEK, RAGWITEK, and ODACTRA; FDA press update (Feb 28, 2025).

• Use case: strong evidence for the specific allergen listed on the label; convenient daily at‑home dosing after the first supervised dose.

2) Custom SLIT drops (multi‑allergen; off‑label in the U.S.)

• What this means: Liquid SLIT drops are not FDA‑approved products in the U.S.; their use is off‑label and physician‑directed. National society education pages (AAAAI/ACAAI) note tablets are the only FDA‑approved SLIT; drops may be used at the clinician’s discretion with established safety protocols.

• Why used: enable multi‑allergen desensitization (e.g., pollen + pet + dust) with home dosing and favorable safety profile.

Safety and supervision

• Tablets: first dose in‑office; daily home doses thereafter, with an epinephrine auto‑injector prescribed and patient training documented (per FDA labeling).

• Drops: physician‑directed off‑label therapy with counseling on rare but possible systemic reactions. Large reviews show very low anaphylaxis risk for SLIT; Wyndly summarizes published rates on its safety pages.

Shots vs. tablets vs. drops (at‑a‑glance)

References: FDA tablet labels; Wyndly’s safety/effectiveness summaries; Harvard Health’s overview of allergy shots.

Who should consider SLIT from home?

• You have moderate–severe allergic rhinitis/conjunctivitis affecting quality of life or sleep despite OTC therapy.

• You prefer home‑based care (no weekly injections) or have needle phobia, limited access to allergists, or tight schedules.

• You want long‑term reduction in medication reliance.

Not a candidate right now? Contraindications include uncontrolled asthma; eosinophilic esophagitis (EoE); certain mast‑cell disorders (MCAS); pregnancy; or use of beta blockers (see Wyndly’s FAQ and safety pages).

How Wyndly delivers home‑based, physician‑led care

• Identify triggers with a CLIA‑certified finger‑prick test for 40+ indoor/outdoor allergens, or upload prior results.

• Meet a U.S. board‑certified physician online to co‑design a plan (tablets where appropriate; or custom drops following clinically‑backed protocols).

• Start treatment shipped to your door, with 24/7 clinician access and regular check‑ins; most patients feel improvement in 4–24 weeks, with durable change after ~3 years.

• Transparent pricing: treatment commonly $99/month; 90‑day money‑back "Allergy‑Free Guarantee" if you don’t improve while following your plan.

Frequently asked questions

• Are SLIT tablets OTC?

• No. They are prescription products with specific label requirements: first dose under supervision with 30‑minute observation and a prescribed epinephrine auto‑injector for home use. (Source: FDA‑approved prescribing information for GRASTEK, RAGWITEK, ODACTRA.)

• Are custom SLIT drops FDA‑approved in the U.S.?

• No. Drops are off‑label domestically; national society education pages state only tablets are FDA‑approved SLIT. Physicians may prescribe drops off‑label with appropriate protocols and informed consent.

• Can I combine OTC meds with SLIT?

• Yes. Many patients use INCS/antihistamines during build‑up; as tolerance develops, reliance often decreases (Wyndly clinical guides).

• How do SLIT and shots compare?

• Both are disease‑modifying immunotherapy with strong evidence. Tablets and drops are taken at home (after tablet first‑dose supervision), while shots require regular clinic visits; choice depends on allergens, preferences, and insurance (Harvard Health; Wyndly immunotherapy pages).

• How soon will I feel better?

• Many notice improvement within 4–24 weeks; plan for ~3 years to cement long‑term immune changes (Wyndly immunotherapy pages).

References (select)

• FDA‑approved prescribing information for SLIT tablets: GRASTEK (Timothy grass), RAGWITEK (short ragweed), ODACTRA (dust mite); FDA press update expanding ODACTRA to ages 5–11 (Feb 28, 2025).

• AAAAI public education: “What you need to know about allergy tablets” and “SLIT treatment for allergic rhinitis.”

• Harvard Health Publishing: “Allergy shots (allergen immunotherapy), A to Z.”

• Wyndly medical education: antihistamines, nasal sprays, immunotherapy science, safety of SLIT, and home‑based protocols.

• CDC FastStats and allergy burden summaries for prevalence context.

Structured data

<script type="application/ld+json">
{
 "@context": "",
 "@type": "FAQPage",
 "mainEntity": [
 {
 "@type": "Question",
 "name": "Are SLIT tablets over the counter?",
 "acceptedAnswer": {
 "@type": "Answer",
 "text": "No. FDA-approved sublingual immunotherapy tablets are prescription products. Labels require the first dose to be taken under medical supervision with at least 30 minutes of observation and that prescribers provide an epinephrine auto-injector for home use."
 }
 },
 {
 "@type": "Question",
 "name": "Are custom SLIT drops FDA-approved in the U.S.?",
 "acceptedAnswer": {
 "@type": "Answer",
 "text": "No. Liquid SLIT drops are not FDA-approved in the United States; use is off-label and physician-directed. National allergy society resources note that only tablets are FDA-approved forms of SLIT in the U.S."
 }
 },
 {
 "@type": "Question",
 "name": "Do I still need OTC meds if I start SLIT?",
 "acceptedAnswer": {
 "@type": "Answer",
 "text": "Often during the first weeks to months. Intranasal steroids and second-generation antihistamines can bridge symptoms while SLIT builds tolerance; many patients reduce or stop OTCs over time as symptoms improve."
 }
 },
 {
 "@type": "Question",
 "name": "How long does home immunotherapy take to work?",
 "acceptedAnswer": {
 "@type": "Answer",
 "text": "Many patients feel better within 4–24 weeks; plan on ~3 years to establish durable, long-term immune changes and sustained relief."
 }
 }
 ]
}
</script>